Probiotic Supplementation in the Dysbiosis of Bowel Preparation
Primary Purpose
Microbial Colonization, Irritable Bowel Syndrome, Metabolic Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Infloran probiotic
HAC probiotic
Infloran placebo
HAC placebo
Sponsored by
About this trial
This is an interventional treatment trial for Microbial Colonization
Eligibility Criteria
Inclusion Criteria:
- Adults age >20
- Undergoing colonofibroscopy (CFS) with PEG bowel preparation
Exclusion Criteria:
- Inadequate bowel preparation
- Subjects with active cancer or IBD (inflammatory bowel disease)
- Subjects with history of abdominal surgery (including stomach, gallbladder, pancreas, small bowel, large bowel)
- Subjects who take medication related to gastrointestinal motility within 1 months
- Subjects who take antibiotics or probiotics within 1 months
- Subjects under pregnancy
- Allergic or intolerance to the study medication
- Refused to randomization
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo
HAC
Infloran
Arm Description
Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
Outcomes
Primary Outcome Measures
Alpha diversity
Change in alpha diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
Beta diversity
Change in beta diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
Bacterial species abundance
Change in abundance of bacterial species post-bowel preparation between probiotic group and placebo group.
Secondary Outcome Measures
Incidence of functional bowel symptoms
Incidence of GI associated symptoms in 8 weeks (abdominal discomfort, diarrhea, constipation, bloating) after bowel preparation between probiotic group (L) and placebo group (P).
BMI
Change in BMI pre- and post-bowel preparation after probiotic or placebo supplementation
Insulin resistance
Change in HOMA-IR pre- and post-bowel preparation after probiotic or placebo supplementation
Dyslipidemia
Change in lipid profiles (T-CHO, LDL, HDL, TG in mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Total cholesterol
Change in Total cholesterol (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
LDL
Change in Low density lipoprotein, LDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
HDL
Change in high density lipoprotein, HDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
TG
Change in triglyceride, TG (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Weight
Change in weight (Kg) pre- and post-bowel preparation after probiotic or placebo supplementation
Waist
Change in Waist (cm) pre- and post-bowel preparation after probiotic or placebo supplementation
Fatty liver (grade)
Change in fatty liver severity (grade) pre- and post-bowel preparation after probiotic or placebo supplementation
Fatty liver (CAP)
Change in fatty liver severity (CAP, dB/m) pre- and post-bowel preparation after probiotic or placebo supplementation
Full Information
NCT ID
NCT04774042
First Posted
February 19, 2021
Last Updated
February 25, 2021
Sponsor
National Taiwan University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04774042
Brief Title
Probiotic Supplementation in the Dysbiosis of Bowel Preparation
Official Title
Probiotic Supplementation in the Dysbiosis of Bowel Preparation
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 2021 (Anticipated)
Primary Completion Date
January 2023 (Anticipated)
Study Completion Date
January 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Significant changes in gut microbiota was noted after the high-volume bowel preparation with PEG before colonoscopy. The dynamic changes were found to be short-term. However, the perturbation pattern of gut microbiota found after bowel preparation may link to metabolic syndrome and obesity. No study had investigated the supplementation of probiotic in this dynamic situation before. Here we proposed this study to fulfill the knowledge gap and also inquiry on the potential therapeutic strategy.1.To test the hypothesis of probiotic supplementation after bowel preparation alters the composition of gut microbiota in a short-term and long-term manner.2.To test the hypothesis of GI tract associated symptoms affected by probiotic supplementation after bowel preparation. 3. To test the hypothesis of clinical events, especially parameters of metabolic syndrome affected by probiotic supplementation after bowel preparation.
Detailed Description
Objectives: Colonoscopy is widely used for identification and treatment of colon polyps and intestinal symptoms. High-volume polyethylene glycol (PEG) bowel preparation prior to colonoscopy causes significant dysbiosis of gut microbiota. Currently dysbiosis of gut microbiota is associated with metabolic syndrome and obesity. However, inconclusive conclusions were drawn from clinical trials studying supplementary probiotics and beneficial clinical effects on metabolic parameters. However, no study has addressed the effects of probiotic supplementation on the labile and dynamic intestinal environment following bowel preparation. Aims: Our study aims at studying the short-term and long-term changes on gut microbiota following the probiotic supplementation after bowel preparation. We also aim at studying the changes in abdominal symptoms and parameters of metabolic syndrome. Methods: This study is a prospective, multicentered, randomized double blind three-armed placebo-controlled trial. Targeted population will be those undergoing PEG bowel preparation before colonoscopy. Each individual will be randomly assigned to one of the active probiotic or placebo supplementation. General health parameters and anthropometric measurements, stool, serum lab data, abdominal sonography, oral carnitine/choline challenge tests will be analyzed. The follow-up timepoints are pre- and post-bowel preparation, receiving probiotics/placebo for 8 weeks, 3 months and 6 months thereafter.Outcome measurement: Primary end point: Evaluate the chronological change of gut microbiota post-bowel preparation between probiotic group and placebo group. Secondary end points:To compare incidence of GI associated symptoms after taking probiotics between two groups. Also evaluate the effects of probiotic supplementation on parameters of metabolic syndrome, evaluate the effects on fatty liver and the interaction between SNP variation and the benefit of probiotic supplementation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Microbial Colonization, Irritable Bowel Syndrome, Metabolic Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
Arm Title
HAC
Arm Type
Experimental
Arm Description
Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
Arm Title
Infloran
Arm Type
Experimental
Arm Description
Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Infloran probiotic
Intervention Description
Infloran
Intervention Type
Dietary Supplement
Intervention Name(s)
HAC probiotic
Intervention Description
HAc probiotic
Intervention Type
Dietary Supplement
Intervention Name(s)
Infloran placebo
Intervention Description
Infloran placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
HAC placebo
Intervention Description
HAC placebo
Primary Outcome Measure Information:
Title
Alpha diversity
Description
Change in alpha diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
Time Frame
32 weeks
Title
Beta diversity
Description
Change in beta diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
Time Frame
32 weeks
Title
Bacterial species abundance
Description
Change in abundance of bacterial species post-bowel preparation between probiotic group and placebo group.
Time Frame
32 weeks
Secondary Outcome Measure Information:
Title
Incidence of functional bowel symptoms
Description
Incidence of GI associated symptoms in 8 weeks (abdominal discomfort, diarrhea, constipation, bloating) after bowel preparation between probiotic group (L) and placebo group (P).
Time Frame
32 weeks
Title
BMI
Description
Change in BMI pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Insulin resistance
Description
Change in HOMA-IR pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Dyslipidemia
Description
Change in lipid profiles (T-CHO, LDL, HDL, TG in mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Total cholesterol
Description
Change in Total cholesterol (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
LDL
Description
Change in Low density lipoprotein, LDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
HDL
Description
Change in high density lipoprotein, HDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
TG
Description
Change in triglyceride, TG (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Weight
Description
Change in weight (Kg) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Waist
Description
Change in Waist (cm) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Fatty liver (grade)
Description
Change in fatty liver severity (grade) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
Title
Fatty liver (CAP)
Description
Change in fatty liver severity (CAP, dB/m) pre- and post-bowel preparation after probiotic or placebo supplementation
Time Frame
32 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adults age >20
Undergoing colonofibroscopy (CFS) with PEG bowel preparation
Exclusion Criteria:
Inadequate bowel preparation
Subjects with active cancer or IBD (inflammatory bowel disease)
Subjects with history of abdominal surgery (including stomach, gallbladder, pancreas, small bowel, large bowel)
Subjects who take medication related to gastrointestinal motility within 1 months
Subjects who take antibiotics or probiotics within 1 months
Subjects under pregnancy
Allergic or intolerance to the study medication
Refused to randomization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tzu-Chan Hong, M.D.
Phone
886-2-972653917
Email
edisonhong77@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Li-Chun Chang, M.D. Ph.D.
Organizational Affiliation
National Taiwan University Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Probiotic Supplementation in the Dysbiosis of Bowel Preparation
We'll reach out to this number within 24 hrs